**Exhibit99.1**

 

**PatentsOwned or Licensed by MedImmune, Inc.**

 
| **Product/  Project** | ** ** | **US Patent  No.** | ** ** | **Subject Matter**                                                                                    | ** ** | **Expiration  Date** | ** ** |
|-----------------------|------------|--------------------|------------|-------------------------------------------------------------------------------------------------------|------------|----------------------|------------|
| E. coli               |       | 4,795,803          |       | Adhesin antigens                                                                                      |       | 1/3/2006             |       |
|                  |       | 5,804,198          |       | Adhesin vaccines                                                                                      |       | 9/8/2015             |       |
|                  |       | 6,291,649          |       | Anti-adhesin antibodies                                                                               |       | 3/2/2005             |       |
|                  |       | 6,500,434          |       | Chaperone and Adhesin Proteins: Vaccines,  Diagnostic and Methods for Treating Infections             |       | 4/23/2019            |       |
|                  |       | 6,737,063          |       | FimH adhesin proteins and methods of use                                                              |       | 7/6/2021             |       |
| Vitaxin               |       | 5,753,230          |       | Use of antibodies anti-avb3  antibodies to inhibit angiogenesis in tumors and inflamed tissue         |       | 5/19/2015            |       |
|                  |       | 6,590,079          |       | Anti-αvβ3 recombinant human  antibodies, nucleic acids encoding same                        |       | 1/30/2017            |       |
|                  |       | 6,531,580          |       | Anti-αvβ3 recombinant human  antibodies, nucleic acids encoding same                        |       | 6/24/2019            |       |
|                  |       | 6,596,850          |       | Anti-αvβ3 recombinant human  antibodies, nucleic acids encoding same                        |       | 1/30/2018            |       |
| MEDI-507              |       | 5,730,979          |       | Anti-CD2 antibodies and their use in  treating T-cell mediated immune responses                       |       | 3/24/2015            |       |
|                  |       | 5,951,983          |       | Anti-CD2 antibodies and their use in treating  T-cell mediated immune responses                       |       | 9/14/2016            |       |
|                  |       | 5,817,311          |       | Use of anti-CD2 antibodies in treating  T-cell mediated immune responses                              |       | 10/6/2015            |       |
|                  |       | 6,849,258          |       | Anti-CD2 antibodies and their use in  treating T-cell mediated immune responses                       |       | 7/18/2017            |       |
| HPV                   |       | 6,261,765          |       | Disassembly/reassembly of Papillomavirus  Virus Like Particles                                        |       | 9/5/2017             |       |
|                  |       | 6,165,471          |       | HPV capsomeres with reduced assembly  capacity                                                        |       | 7/2/2018             |       |
|                  |       | 6,153,201          |       | Oral Immunization with Papillomavirus Virus  Like Particles                                           |       | 3/9/2013             |       |
|                  |       | 6,416,945          |       | Disassembly/reassembly of Papillomavirus  Virus Like Particles                                        |       | 9/5/2017             |       |
| RSV                   |       | 5,824,307          |       | SynagisÒ  & other anti-RSV antibodies and their use in treating or preventing RSV  infection |       | 10/20/2015           |       |
|                  |       | 5,582,827          |       | Immunoglobulin from plasma for treatment of  RSV                                                      |       | 12/10/2013           |       |
|                  |       | 4,800,078          |       | Treatment of respiratory disease caused by  RSV using human gamma globulin                            |       | 1/24/2006            |       |
|                  |       | 5,412,077          |       | Effective Antibody Titers Against  Respiratory Viruses                                                |       | 8/4/2020             |       |

 

----

 
|   |   | 6,565,849 |   | Methods of Enhancing Activity of Vaccines  and Vaccine Compositions                                        |   | 3/02/2021  |   |
|--------|--------|-----------|--------|------------------------------------------------------------------------------------------------------------|--------|------------|--------|
|   |   | 6,818,216 |   | Methods of administering/dosing anti-RSV  antibodies for prophylaxis and treatment                         |   | 11/28/2020 |   |
| Strep  |   | 5,928,900 |   | Pad1 protein                                                                                               |   | 7/27/2016  |   |
|   |   | 5,981,229 |   | DNA encoding Exp1 and PlpA proteins                                                                        |   | 11/9/2016  |   |
|   |   | 5,834,278 |   | DNA encoding pneumococcal MsrA                                                                             |   | 5/1/2016   |   |
|   |   | 6,245,335 |   | Streptococcal choline binding proteins                                                                     |   | 5/1/2017   |   |
|   |   | 5,736,367 |   | Vectors and Prokaryotes which  Autocatalytically Delete Resistance                                         |   | 4/7/2018   |   |
|   |   | 5,798,243 |   | Bacterial Peptide Methionine Sulfoxide Reductase  an Adhesion Associated Protein, and Antibiotic Therapies |   | 5/1/2016   |   |
|   |   | 6,420,135 |   | Streptococcus pneumoniae polynucleotides and sequences                                                     |   | 10/03/17   |   |
|   |   | 6,503,511 |   | Derivatives of Choline Binding Proteins for Vaccines                                                       |   | 4/6/2019   |   |
|   |   | 6,582,706 |   | Streptococcus Pneumoniae Protein and Immunogenic Fragments for  Vaccine                                    |   | 12/21/2019 |   |
|   |   | 6,689,369 |   | Immunogenic pneumococcal protein and vaccine compositions thereof                                          |   | 1/17/2022  | (a)    |
|   |   | 6,784,164 |   | Choline binding proteins for anti-pneumococcal vaccines                                                    |   | 5/1/2017   |   |
|   |   | 6,833,356 |   | Pneumococcal protein homologs and fragments  for vaccines                                                  |   | 3/10/2021  | (a)    |
| IL-9   |   | 5,157,112 |   | Antibodies which specifically bind  mammalian T cell growth factor P40                                     |   | 10/20/2009 |   |
|   |   | 6,037,149 |   | DNA and RNA molecules that encode Met-IL-9  and their use for recombinant production                       |   | 8/23/2016  |   |
|   |   | 5,580,753 |   | DNA molecules encoding IL-9 and their use  for recombinant production                                      |   | 12/3/2013  |   |
|   |   | 5,734,037 |   | Nucleic acid molecules that hybridize to  DNA encoding IL-9                                                |   | 5/23/2009  |   |
|   |   | 5,414,071 |   | Human IL-9 protein                                                                                         |   | 5/9/2012   |   |
|   |   | 5,164,317 |   | Method for enhancing proliferation of mast  cells using IL-9                                               |   | 3/23/2010  |   |
|   |   | 5,132,109 |   | Method for enhancing IgG production using  IL-9 and IL-4                                                   |   | 10/5/2010  |   |
|   |   | 5,246,701 |   | Method to inhibit IgE production using  anti-IL-9 antibodies or other IL-9 inhibitors                      |   | 10/5/2010  |   |
|   |   | 5,962,269 |   | Processes and hybridomas for producing  anti-IL-9 receptor antibodies                                      |   | 10/5/2016  |   |
|   |   | 6,261,559 |   | Treating asthmatic symptoms using anti-IL-9  antibodies                                                    |   | 8/23/2016  |   |
|   |   | 5,789,237 |   | Nucleic acid molecules that hybridize to  DNAs encoding human and murine IL-9 receptors                    |   | 8/4/2015   |   |

 

----

 
|   |   | 5,750,377 |   | Methods for production of mammalian T cell  growth factor P40                                                                                                                                                                                                                                       |   | 5/12/2015  |   |
|--------|--------|-----------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------|--------|
|   |   | 5,116,951 |   | IL-9 receptor protein                                                                                                                                                                                                                                                                               |   | 9/19/2010  |   |
|   |   | 5,587,302 |   | Nucleic acid molecules encoding mammalian T  cell growth factor P40                                                                                                                                                                                                                                 |   | 12/24/2013 |   |
|   |   | 5,208,218 |   | Mammalian T cell growth factor P40 protein                                                                                                                                                                                                                                                          |   | 5/4/2010   |   |
|   |   | 5,180,678 |   | Methods of detecting IL-9                                                                                                                                                                                                                                                                           |   | 9/19/2010  |   |
|   |   | 6,602,850 |   | Method of treating asthma using soluble  IL-9 receptor variants                                                                                                                                                                                                                                     |   | 8/23/2016  |   |
|   |   | 6,645,492 |   | Asthma associated factors as targets for  treating atopic allergies including asthma and related disorders                                                                                                                                                                                          |   | 8/23/2016  |   |
| Ethyol |   | 5,292,497 |   | Improving toxicity profiles in chemotherapy                                                                                                                                                                                                                                                         |   | 3/29/2011  |   |
|   |   | 5,424,471 |   | Process for preparing crystalline forms                                                                                                                                                                                                                                                             |   | 7/13/2012  |   |
|   |   | 5,591,731 |   | Dosage forms of crystalline amifostine                                                                                                                                                                                                                                                              |   | 7/31/2012  |   |
|   |   | 5,824,664 |   | Agents and methods for inhibiting HIV viral  and protein expression using compounds that belong to a family which contains  amifostine                                                                                                                                                              |   | 10/20/2015 |   |
|   |   | 5,846,958 |   | Methods of stimulating hematopoietic  progenitor cells using a compound that belong to a family which contains  amifostine                                                                                                                                                                          |   | 12/8/2015  |   |
|   |   | 5,906,984 |   | Methods of stimulating hematopoietic  progenitor cells using specific compounds, which include amifostine                                                                                                                                                                                           |   | 2/17/2015  |   |
|   |   | 5,994,409 |   | Methods of treating toxicities associated  with chemotherapy, a method of treating a nephrodisorder, and a method of  treating xerostomia, all of which use a compound that belongs to a family  which contains amifostine                                                                          |   | 12/9/2017  |   |
|   |   | 6,051,563 |   | Subcutaneous administration, method of  protecting against toxicities associated with ionizing radiation                                                                                                                                                                                            |   | 2/12/2017  |   |
|   |   | 6,127,351 |   | Methods of treating or protecting against  toxicities associated with chemotherapy using a specific dosing regime, a  method of stimulating bone marrow growth, and a method of treating  myelodysplastic syndrome, all of which use a compound that belongs to a  family which contains amifostine |   | 2/12/2017  |   |
|   |   | 6,218,377 |   | Methods of treating or protecting against  toxicities associated with specific chemotherapy agents, and a method of  protecting normal tissue in cancer patients, both of which use a compound  that belongs to a family which contains amifostine                                                  |   | 2/12/2017  |   |
|   |   | 6,239,119 |   | Methods of treating damaged or infected  mucosal tissue using a compounds that belongs to a family which contains  amifostine                                                                                                                                                                       |   | 4/26/2019  |   |
|   |   | 6,384,259 |   | Stable Amorphous Amifostine Composition and  Methods for the Preparation and Use of the Same                                                                                                                                                                                                        |   | 11/16/2018 |   |

 

----

 
|      |   | 6,407,278 |   | Stable Amorphous Amifostine Composition and  Methods for the Preparation and Use of the Same               |   | 11/16/2018 |   |
|-----------|--------|-----------|--------|------------------------------------------------------------------------------------------------------------|--------|------------|--------|
|      |   | 6,489,312 |   | Novel Pharmaceutical Formulations  Comprising Aminoalkyl Phosphorothioates                                 |   | 6/15/2019  |   |
|      |   | 6,586,476 |   | Methods for Treatment of Neuro and Nephro  Disorders and Therapeutic Toxicities Using Aminothiol Compounds |   | 12/09/2017 |   |
|      |   | 6,573,253 |   | Methods of the Administration of Amifostine  and Related Compounds                                         |   | 2/12/2017  |   |
|      |   | 6,753,323 |   | Topical administration of Amifostine and  Related Compounds                                                |   | 9/27/2019  | (a)    |
| NeuTrexin |   | 5,716,960 |   | Cystalline glucuronate hydrate salt                                                                        |   | 2/10/2015  |   |
|      |   | 4,853,221 |   | Method for treating non-small cell lung  cancer, head and neck cancers and breast cancer                   |   | 8/1/2006   |   |
|      |   | 6,017,921 |   | Crystalline glucuronate salt                                                                               |   | 1/13/2015  |   |
|      |   | 6,017,922 |   | Thermally stable crystalline non-salts                                                                     |   | 5/18/2018  |   |
|      |   | 6,258,821 |   | Trimetrexate ascorbate and compositions  comprising trimetrexate and ascorbic acid                         |   | 4/26/2019  |   |
|      |   | 6,258,952 |   | Methods of producing monohydrate                                                                           |   | 5/18/2018  |   |
|      |   | 4,694,007 |   | Use of Trimetrexate as Antiparasitic Agent                                                                 |   | 9/15/2006  |   |
|      |   | 4,677,219 |   | Substituted Benzonitriles                                                                                  |   | 7/17/2006  |   |
|      |   | 5,160,727 |   | Tumor Cell Sensitization Method                                                                            |   | 3/21/2010  |   |
|      |   | 6,576,635 |   | Novel Compositions Comprising Trimetrexate                                                                 |   | 10/26/2019 |   |
| PALA      |   | 5,491,135 |   | Methods of treating a viral infections (*e.g.*, hepatitis B and C and secondary to  HIV 1)                 |   | 2/13/2013  |   |
| Platinum  |   | 4,895,935 |   | Platinum Pharmaceuticals                                                                                   |   | 1/23/2007  |   |
|      |   | 4,895,936 |   | Platinum Pharmaceuticals                                                                                   |   | 1/23/2007  |   |
|      |   | 4,957,481 |   | Photodynamic therapeutic technique                                                                         |   | 9/18/2007  |   |
| CMV       |   | 6,291,236 |   | Human CMV sequences and attenuated viruses                                                                 |   | 3/31/2015  |   |
|      |   | 5,925,751 |   | Human CMV sequences and attenuated viruses                                                                 |   | 3/31/2015  |   |
|      |   | 5,721,354 |   | Human CMV sequences and attenuated viruses                                                                 |   | 3/31/2015  |   |
|      |   | 6,040,170 |   | Human CMV sequences and attenuated viruses                                                                 |   | 3/31/2015  |   |
|      |   | 6,635,477 |   | Human CMV sequences and attenuated viruses                                                                 |   | 3/31/2015  |   |
| EBV       |   | 6,054,130 |   | Non-splicing variants of EBV gp350 protein  and gene                                                       |   | 4/18/2014  |   |
|      |   | 5,824,508 |   | Non-splicing variants of EBV gp350 protein  and gene                                                       |   | 4/18/2014  |   |

 

----

 
|                           |   | 6,458,364 |   | Non-Splicing Variants of GP350/220                               |   | 4/18/2014  |   |
|--------------------------------|--------|-----------|--------|------------------------------------------------------------------|--------|------------|--------|
|                           |   | 6,692,749 |   | Non-Splicing Variants of GP350/220                               |   | 4/18/2014  |   |
| Influenza                      |   | 5,690,937 |   | Temperature sensitive mutants of influenza                       |   | 6/5/2015   |   |
|                           |   | 6,090,391 |   | Recombinant tryptophan mutants of influenza  PB2 gene            |   | 2/23/2016  |   |
|                           |   | 6,322,967 |   | Recombinant tryptophan mutants of influenza  PB2 gene            |   | 2/23/2016  |   |
|                           |   | 6,528,064 |   | Recombinant tryptophan mutants of influenza                      |   | 2/23/2016  |   |
|                           |   | 6,843,996 |   | Recombinant Temperature sensitive mutants  of influenza          |   | 6/5/15     |   |
| HSV                            |   | 4,769,331 |   | Recombinant herpes simplex cloning methods  and materials        |   | 9/6/2005   |   |
|                           |   | 4,859,587 |   | Recombinant herpes simplex vectors and  vaccines                 |   | 8/22/2006  |   |
|                           |   | 5,288,641 |   | Herpes simplex as a vector                                       |   | 2/22/2011  |   |
|                           |   | 5,328,688 |   | Recombinant herpes simplex with 34.5 gene  knockout              |   | 6/12/2011  |   |
|                           |   | 5,599,691 |   | Herpes simplex as a vector                                       |   | 2/4/2014   |   |
|                           |   | 5,641,651 |   | Synthetic HSV promoters and uses                                 |   | 6/24/2014  |   |
|                           |   | 5,714,153 |   | Recombinant herpes simplex vaccines and  vectors                 |   | 12/23/2012 |   |
|                           |   | 5,922,328 |   | Gamma 34.5 mutants of herpes simplex  viruses                    |   | 9/11/2016  |   |
|                           |   | 6,071,692 |   | Herpes simplex as a gene expression vector  and vaccine          |   | 6/4/2004   |   |
|                           |   | 6,120,773 |   | Gamma 34.5 gene modification of herpes  simplex viruses          |   | 9/19/2017  |   |
| Negative  Stranded RNA Viruses |   | 5,166,057 |   | Recombinant negative strand RNA viruses                          |   | 11/24/2009 |   |
|                           |   | 5,578,473 |   | Recombinant negative strand RNA viruses                          |   | 11/24/2009 |   |
|                           |   | 5,786,199 |   | Recombinant negative strand RNA viruses and  vaccines            |   | 7/28/2015  |   |
|                           |   | 5,820,871 |   | Recombinant negative strand RNA viruses –  bicistronic      |   | 10/13/2015 |   |
|                           |   | 5,840,520 |   | Recombinant negative strand RNA virus  expression systems        |   | 8/28/2009  |   |
|                           |   | 5,854,037 |   | Recombinant negative strand RNA viruses                          |   | 12/29/2015 |   |
|                           |   | 6,001,634 |   | Recombinant negative strand RNA viruses                          |   | 8/28/2009  |   |
|                           |   | 6,022,726 |   | Attenuated negative strand RNA viruses and  methods              |   | 2/8/2017   |   |
|                           |   | 6,316,243 |   | Recombinant attenuated double strand RNA  viruses                |   | 11/13/2018 |   |
|                           |   | 6,764,685 |   | Recombinant parainfluenza virus expression  systems and vaccines |   | 3/21/2020  |   |
|                           |   | 6,811,784 |   | Recombinant parainfluenza virus expression  systems and vaccines |   | 3/21/2021  |   |

 

----

 
| VZV             |   | 6,087,170 |   | VZV gene and mutant VZV viruses                                                                                              |   | 4/28/2014 |   |
|-----------------|--------|-----------|--------|------------------------------------------------------------------------------------------------------------------------------|--------|-----------|--------|
|            |   | 6,713,296 |   | VZV gene, mutant VZV and immunogenic compositions                                                                            |   | 4/28/2014 |   |
| HMGB1           |   | 6,468,533 |   | Antagonists of HMG1 for treating  inflammatory conditions                                                                    |   | 2/11/2019 |   |
|            |   | 6,448,223 |   | Antagonists of HMG1 for treating  inflammatory conditions                                                                    |   | 2/11/2019 |   |
|            |   | 6,303,321 |   | Antagonists of HMG1 for treating  inflammatory conditions                                                                    |   | 2/11/2019 |   |
| IFNα IFNR1 |   | 5,889,151 |   | Purified human alpha interferon receptor                                                                                     |   | 3/30/2016 |   |
|            |   | 5,886,153 |   | Antibodies directed against the alpha  interferon receptor                                                                   |   | 6/6/2016  |   |
|            |   | 5,731,169 |   | cDNA fragment coding the alpha interferon  receptor gene and process for the preparation of a corresponding protein          |   | 6/6/2015  |   |
|            |   | 5,861,258 |   | Use of the alpha interferon receptor and  cells which express the receptor, for identification of alpha interferon  agonists |   | 6/6/2016  |   |
|            |   | 5,919,453 |   | Monoclonal antibodies against the  interferon receptor, with neutralizing activity against type I interferon                 |   | 12/5/2016 |   |
|            |   | 6,787,634 |   | Isolated peptide or polypeptide of the  extracellular portion of the human interferon receptor (IFN-R)                       |   | 12/6/2014 |   |
|            |   | 6,475,983 |   | Water-soluble polypeptides having a high  affinity for alpha and beta interferons                                            |   | 11/5/2019 |   |

 

----

(a) Calculation of expiration date includespatent term adjustment

 

----